ArticleEJNMMI research2021
Benefits and harms of implementing [
Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparing the diagnostic efficacy of [Frontiers in medicine · 2025Pooled it
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Site-Specific Patterns of Distant Relapse on ^18F-FDG PET/Contrast-Enhanced CT According to Molecular Subtype in Breast Cancer: A Retrospective Cohort Study.Nuclear medicine and molecular imaging · 2026Article
- 18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting.Acta oncologica (Stockholm, Sweden) · 2024Article
- Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer.Breast cancer research and treatment · 2024Article
- Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer.Medicina (Kaunas, Lithuania) · 2024Review
- The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [Journal of imaging · 2023Article
- 2-[Scientific reports · 2023Article
- Response Monitoring in Metastatic Breast Cancer: A Prospective Study ComparingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- State of the Art in 2022 PET/CT in Breast Cancer: A Review.Journal of clinical medicine · 2023Review
- Prone versus Supine FDG PET/CT in the Staging of Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Imaging for illuminating actionable pathways in breast cancer.Current opinion in oncology · 2022Review
- Image quality evaluation of real low-dose breast PET.Japanese journal of radiology · 2022Article
- Synchronous Malignancies Identified by PET-CT Scan in Breast Cancer Patients.Rambam Maimonides medical journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
background[
methodsWomen with suspected distant recurrent breast cancer were prospectively enrolled in the study between September 2017 and August 2019. [
results[
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.